SHANDONG XINHUA (00719) has announced that the company recently received the "Drug Registration Certificate" for Ambroxol and Clenbuterol Oral Solution, approved and issued by the National Medical Products Administration (NMPA). In May 2024, Xinhua Pharmaceutical submitted the application materials for the marketing authorization of Ambroxol and Clenbuterol Oral Solution to the Center for Drug Evaluation (CDE) of the NMPA, which was accepted. The "Drug Registration Certificate" was obtained in May 2026, with the evaluation conclusion stating: registration approved. This product is indicated for the treatment of cough, viscous sputum, difficulty in expectoration, and wheezing caused by acute and chronic respiratory diseases (such as acute and chronic bronchitis, emphysema, etc.). According to relevant statistical data, the sales of Ambroxol and Clenbuterol Oral Solution in Chinese public medical institutions in 2024 amounted to approximately RMB 740 million.